Oxford BioMedica PLC (OXBDF)

[georgejjl]

Marcus

Since the lentivector is an absolutely critical part of CTL019, I suspect that the royalties due to Oxford BioMedica may be in the range of 3 to 10% and possibly higher.

Since CTL-019 may be effective against various leukemia's, lymphoma's and myeloma's, there is still need to expand this type of Chimerical Antigen Receptor treatment for various solid tumors.

Oxford BioMedica is currently working on CART 5T4 as a potentially most potent treatment (cure) for a very wide variety of solid tumors.

Watch the video at the link below, then think about a wide variety of solid tumors.

http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019

Good luck and GOD bless,

George